Mahajoub Bello-Roufai

Mahajoub Bello-Roufai has a strong background in technical operations and process development within the biotechnology and pharmaceutical industries. Mahajoub has held various leadership positions in companies such as Akron Bio, Voyager Therapeutics, Ology Bioservices, and Florida Biologix.

At Akron Bio, Bello-Roufai is currently serving as the Vice President of Research & Process Development since May 2023. Prior to this role, they had a series of positions at Voyager Therapeutics, including Senior Director of Technical Operations from July 2022 to July 2023, Director of Program Development from October 2021 to July 2022, and Associate Director of CMC & External Manufacturing/Supply from April 2019 to October 2021. In these roles, they were responsible for managing cross-functional teams, overseeing manufacturing activities, and facilitating technology transfer processes.

Before joining Voyager Therapeutics, Bello-Roufai worked at Ology Bioservices as a Senior Manager of Scientific Operations and Technology Transfer from September 2018 to April 2019. Prior to this, they held positions as a Senior Manager of Upstream and Downstream BioManufacturing from August 2016 to August 2018 and a Manager of Upstream and Downstream BioManufacturing from August 2015 to August 2016. In these roles, they focused on process development, optimization, and facility management.

Bello-Roufai's early career includes positions at Florida Biologix (Currently ThermoFisher VVS), where they served as the Director of Upstream Process Development and Manufacturing from May 2014 to July 2015. Before this, they were the Research Program and Services Coordinator, responsible for leading cell culture-based upstream production activities and managing the quality control laboratory. Mahajoub began their career at Florida Biologix as a Scientific Research and Process Development Manager, where they oversaw process development and cGMP production of recombinant proteins and viral vectors.

Overall, Bello-Roufai has extensive experience in technical operations, process development, manufacturing, and technology transfer within the biotechnology industry.

Mahajoub Bello-Roufai obtained their Doctor of Philosophy (Ph.D.) degree in Molecular and Cellular Biology and Biophysics from Université d'Orléans. Mahajoub'sfield of study during the period from 1997 to 2001 was Nucleic Acid Transfer/Gene Therapy.